InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $16.090 0.19 (1.19%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,469 Appendix 4E and 2023 Annual Report 22 Feb 2024 6:34PM $10.970 $16.090 risen by 46.67%
$5,469 Cleansing Notice 9 Feb 2024 8:22AM $12.000 $16.090 risen by 34.08%
$5,469 Application for quotation of securities - TLX 9 Feb 2024 8:22AM $12.000 $16.090 risen by 34.08%
$5,469 Proposed issue of securities - TLX 8 Feb 2024 8:17AM $11.860 $16.090 risen by 35.67%
$5,469 Presentation to Accompany QSAM Acquisition 8 Feb 2024 8:17AM $11.860 $16.090 risen by 35.67%
$5,469 Telix Acquires QSAM and its Bone Cancer Targeting Platform 8 Feb 2024 8:17AM $11.860 $16.090 risen by 35.67%
$5,469 Telix 2023 Full Year Results and Investor Webcast/Call 7 Feb 2024 8:13AM $11.900 $16.090 risen by 35.21%
$5,469 Appendix 3Y Change in Director Interests - C Behrenbruch 22 Jan 2024 8:24AM $11.240 $16.090 risen by 43.15%
$5,469 Cleansing Notice 22 Jan 2024 8:23AM $11.240 $16.090 risen by 43.15%
$5,469 Application for quotation of securities - TLX 22 Jan 2024 8:22AM $11.240 $16.090 risen by 43.15%
$5,469 JP Morgan Healthcare Conference Presentation 8 Jan 2024 5:12PM $9.170 $16.090 risen by 75.46%
$5,469 JP Morgan Healthcare Conference and Trading Update 8 Jan 2024 5:11PM $9.170 $16.090 risen by 75.46%
$5,469 Notification regarding unquoted securities - TLX 8 Jan 2024 8:25AM $9.550 $16.090 risen by 68.48%
$5,469 Notification of cessation of securities - TLX 8 Jan 2024 8:24AM $9.550 $16.090 risen by 68.48%
$5,469 Telix Plans U.S. Registered Public Offering and Listing 5 Jan 2024 8:24AM $9.530 $16.090 risen by 68.84%
$5,469 Cleansing Notice 22 Dec 2023 8:24AM $9.780 $16.090 risen by 64.52%
$5,469 Application for quotation of securities - TLX 22 Dec 2023 8:24AM $9.780 $16.090 risen by 64.52%
$5,469 Appointment of Dr David Cade to Group Chief Medical Officer 20 Dec 2023 8:19AM $9.790 $16.090 risen by 64.35%
$5,469 Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging 19 Dec 2023 8:22AM $9.560 $16.090 risen by 68.31%
$5,469 Update on Financial Reporting Requirements 18 Dec 2023 8:33AM $9.400 $16.090 risen by 71.17%
$5,469 Cleansing Notice 30 Nov 2023 8:20AM $9.670 $16.090 risen by 66.39%
$5,469 Application for quotation of securities - TLX 30 Nov 2023 8:20AM $9.670 $16.090 risen by 66.39%
$5,469 Telix ProstACT (TLX591) Expert Forum - Webcast Notification 16 Nov 2023 2:41PM $8.945 $16.090 risen by 79.88%
$5,469 Telix Announces Proposed Acquisition of QSAM Biosciences 14 Nov 2023 9:20AM $9.150 $16.090 risen by 75.85%
$5,469 First Patient Dosed in Ph III ProstACT GLOBAL Therapy Study 13 Nov 2023 8:32AM $9.450 $16.090 risen by 70.26%

351 - 375 of 961 results

Page 15 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.